Increased levels of adiponectin in non-human primates and humans with metabolic disease (type 2 diabetes, obesity and NASH) have been consistently observed following treatment with various FGF21 analogs (183, 244–246). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.